New drug combo and radiation for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have stage IV colorectal cancer that is MSS (microsatellite stable).
- You have already tried at least two standard chemotherapy treatments, and they didn't work or caused too many side effects.
- You are in good general health (able to do daily activities without help).
- You have not received immunotherapy (like PD-1 or CTLA-4 inhibitors) before.
- You do not have an active autoimmune disease (like Crohn's, rheumatoid arthritis, or lupus).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three treatments (a drug called QL1706, a targeted therapy called fruquintinib, and a short course of radiation) for people with colorectal cancer that has spread to the liver and has normal DNA repair. The goal is to see if this combination works better than the usual third-line therapy.
This trial tests a new drug combo (fruquintinib and sintilimab) with or without radiation for people with colorectal cancer that has spread to the liver and has not responded to earlier treatments.
This trial tests a combination of two oral chemotherapy drugs, fruquintinib and S-1, for people with metastatic colorectal cancer that has worsened after standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This trial tests a combination of two oral drugs (fruquintinib and camrelizumab) plus a chemotherapy infusion directly into the liver artery (HAIC) for people with advanced colorectal cancer that has spread to the liver. It's for those whose first treatment has stopped working and whose cancer is not the MSI-H type.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.